Even though the prognostic/predictive role of TP53 and PIK3CA mutations has been addressed in a considerable number of studies, information regarding their role with respect to specific breast cancer subtypes within the context of adjuvant trials remains limited. The gene discussed is TP53; the disease is breast carcinoma.